This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pyruvate dehydrogenase complex deficiency / PDHA1/PDHB/DLAT/DLD deficiency탈수소효소피루브산염의 결핍 / 피루브산염대사 및 포도당신합성 장애

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.4 (disorders of pyruvate metabolism and gluconeogenesis) | Special Copayment Reduction: V117 (rare disease)
B. SynonymsPyruvate dehydrogenase deficiency (PDH deficiency, PDCD), E1α deficiency (PDHA1 deficiency), E1β deficiency (PDHB deficiency), E2 deficiency (DLAT deficiency), E3 deficiency (DLD deficiency), pyruvate dehydrogenase complex deficiency, Leigh syndrome (PDH-associated)
C. Adult onsetLikelihood of adult onset possible (mild form) — in mild variants with some residual enzyme activity preserved, it may first be diagnosed in adulthood with exercise intolerance, recurrent lactic acidemia and mild cognitive decline. However, it mostly manifests in the neonatal period to infancy.
1. History1970 first description of PDH deficiency by Blass → 1975 enzyme complex structure elucidated → 1984 PDHA1 gene cloned → 1990s ketogenic diet treatment established → 2020s research on thiamine and gene therapy under way.
2. CausesVariants in genes for PDH complex component proteins: PDHA1 (Xp22.12, X-linked, most common), PDHB (3p14.3), DLAT (11q23.1), DLD (7q31.1), PDHX (11p13). Blocked conversion of pyruvate → acetyl-CoA → lactate accumulation.
3. GeneticsPDHA1: X-linked (hemizygous, or dominant with incomplete penetrance). Others: autosomal recessive. PDHA1 deficiency accounts for about 60–70% of all cases. De novo variants frequent (boys); symptoms in heterozygous females variable.
4. General epidemiologyThe most common single-enzyme cause among mitochondrial energy metabolism disorders. Incidence ~1:100,000. Sex: because PDHA1 is X-linked, severe manifestation mostly in males. Variable phenotype in heterozygous females.
5. PathophysiologyPDH complex deficiency → blocked conversion of pyruvate to acetyl-CoA → accumulation of pyruvate and lactate (lactic acidosis) → insufficient substrate for the TCA cycle and oxidative phosphorylation → brain energy depletion → neurodevelopmental disorders and Leigh lesions.
6. SymptomsSevere neonatal: severe lactic acidosis, hypotonia, encephalopathy. Infantile form: developmental delay, seizures, exercise intolerance. Leigh syndrome form: recurrent brainstem lesions, regression. Mild intermittent form: episodes of lactic acidosis after carbohydrate loading.
7. SignsElevated blood lactate and pyruvate (lactate/pyruvate ratio normal or mildly elevated). Elevated plasma alanine. Brain MRI: symmetric T2 hyperintense lesions in the basal ganglia and brainstem (Leigh pattern). Muscle biopsy: abnormal mitochondrial morphology.
8. ScreeningBlood amino acids (elevated alanine), blood lactate/pyruvate ratio. In neonatal lactic acidosis, suspect PDH deficiency when the lactate/pyruvate ratio is < 25. Suspected based on a combination of clinical and biochemical findings.
9. DiagnosisPlasma lactate, pyruvate and alanine. Brain MRI. Measurement of PDH complex activity in skin fibroblasts or lymphoblasts. Molecular genetic testing (PDHA1/PDHB/DLAT/DLD/PDHX NGS). Muscle biopsy (if needed).
10. TreatmentKetogenic diet: the main treatment. A high-fat, low-carbohydrate diet switches the brain's energy supply pathway. Trial of high-dose thiamine (vitamin B1) (responsive variants exist). Dichloroacetate (DCA): activates pyruvate dehydrogenase. Coenzyme Q10.
11. PrognosisSevere neonatal form: early death or severe neurologic impairment. Leigh syndrome form: recurrent episodes of regression, death possible within years. Mild form responsive to ketogenic diet: relative stabilization possible. Overall prognosis poor.
12. PreventionGenetic counseling, prenatal diagnosis. Early start of ketogenic diet. Avoidance of metabolic stress such as carbohydrate loading, fever and infection. PDHA1 X-linked: genetic counseling essential for carrier females.
13. ReferencesPatel KP et al. 2012; Brown GK et al. 1994; Strafella C et al. 2026 and 7 other references.

1. History

The first clinical description of pyruvate dehydrogenase complex deficiency (PDCD) began in 1970 when J.P. Blass in the United States first reported markedly reduced pyruvate dehydrogenase (PDH) complex activity in skin fibroblasts of a boy with neurodevelopmental impairment, lactic acidosis and ataxia. This report is historically significant as the first case explicitly showing that a disorder of mitochondrial energy metabolism can be an independent cause of central nervous system disease.

The biochemical structure of the PDH complex was intensively elucidated in the 1970s–80s. The complex consists of three catalytic subunits (pyruvate decarboxylase E1, a heterodimer of E1α/E1β; dihydrolipoamide acetyltransferase E2; dihydrolipoamide dehydrogenase E3), two regulatory subunits (PDH kinase PDK, PDH phosphatase PDP) and the E3-binding protein (E3BP; PDHX). Cloning of PDHA1 (the E1α gene) was completed in 1984, and the PDHB (E1β), DLAT (E2), DLD (E3) and PDHX (E3BP) genes were subsequently identified in turn.

In the history of treatment, the ketogenic diet was established as the main treatment for PDCD in the 1980s–90s. The ketogenic diet, which minimizes carbohydrates and makes fat the main source of energy, supplies the brain with ketone bodies (acetoacetate, β-hydroxybutyrate) instead of glucose, providing an alternative energy pathway that bypasses the PDH complex. Dichloroacetate (DCA) is used through a mechanism of amplifying residual PDH activity by inhibiting PDH kinase (PDK) and promoting dephosphorylation (activation) of the PDH complex. High-dose thiamine (vitamin B1) has shown some responsiveness in patients with variants near the TDP-binding site of E1α, so a trial at diagnosis has been standardized. Research on gene therapy, enzyme replacement and mRNA-based therapy is currently under way.

Regarding the association between Leigh syndrome (subacute necrotizing encephalomyelopathy) and PDCD, after Denis Leigh first described the characteristic brainstem and basal ganglia lesions in the 1950s, PDCD was confirmed in the era of molecular diagnosis to be one of the causes of Leigh syndrome. However, Leigh syndrome is a heterogeneous syndrome that also arises from various other causes such as mitochondrial respiratory chain complex deficiencies.


2. Causes

The pyruvate dehydrogenase complex (PDH complex, PDHC) is a key metabolic enzyme complex in the mitochondrial matrix that oxidatively decarboxylates pyruvate to acetyl coenzyme A (acetyl-CoA). This reaction is the irreversible step linking pyruvate, the product of glycolysis, to the TCA cycle (citric acid cycle) and oxidative phosphorylation. In PDHC deficiency, pyruvate cannot be converted to acetyl-CoA and is instead converted to lactate and alanine, which accumulate in excess in the blood.

PDHC deficiency is caused by pathogenic variants in several genes encoding the component proteins of the complex.

In some patients, PDH kinase (PDK) or PDH phosphatase (PDP1) deficiency has been reported to cause a PDCD-like phenotype. PDH activity can also be reduced by acquired causes such as vitamin B1 (thiamine) deficiency and arsenic poisoning, but these are secondary causes, not genetic diseases.


3. Genetics

The PDHA1 gene is located on the short arm of the X chromosome (Xp22.12) and has 11 exons. The encoded E1α has 390 amino acids; two E1α and two E1β combine to form an (αβ)₂ tetramer, and this E1 binds to the E2 scaffold to make up the entire PDH complex. PDHA1 variants are highly diverse (point mutations, small deletions, splicing variants, large deletions/duplications, etc.), and more than 300 have been reported to date. About 50–65% of PDHA1 variants arise as de novo variants, so the disease occurs even without a family history.

A distinctive aspect of PDHA1 inheritance is clinical expression in heterozygous females. Depending on the X-inactivation ratio, a broad spectrum is possible, from asymptomatic carriers to a severe neurologic phenotype. The X-inactivation pattern in brain tissue is the key factor determining clinical severity, and because the X-inactivation pattern in blood can differ from that in brain tissue, clinical prediction is difficult.

The remaining genes (PDHB, DLAT, DLD, PDHX) are all located on autosomes and inherited in an autosomal recessive manner. Because DLD gene variants impair multiple metabolic complexes simultaneously, a more complex clinical phenotype (with organic acidemia, hyperammonemia, etc.) may appear.

Molecular genetic testing is performed with an NGS panel (mitochondrial disease panel or whole exome analysis). If no PDHA1 variant is detected, MLPA analysis is used to check for large deletions/duplications. Mitochondrial genome analysis is also performed concurrently to differentiate Leigh syndrome.


4. General epidemiology

PDCD is one of the most common single-enzyme deficiency causes among mitochondrial energy metabolism disorders. The incidence is estimated at about 1:100,000 births, but because mild variants often go undiagnosed, it is likely actually higher. Several thousand confirmed patients have been reported worldwide.

In sex distribution, PDHA1 deficiency (about 60–70% of all cases) is X-linked, so male patients are relatively more numerous and severe manifestation is more common. Heterozygous females range from mild to severe, and some females show a more severe phenotype than male patients. Patients with PDHB, DLAT, DLD and PDHX deficiency show no sex difference because these are autosomal recessive.

Differences in frequency by ethnicity or region are not clear, but founder variants have been reported in certain ethnic groups. Case reports are also rare in Korea, and diagnosis and treatment are provided at specialized mitochondrial disease centers in Korea. Medical cost support is provided through Special Copayment Reduction V117 registration. Early suspicion is possible on newborn screening through blood amino acids (elevated alanine) and blood lactate measurement, but additional testing is needed for confirmation.


5. Pathophysiology

The PDH complex converts pyruvate to acetyl-CoA in the mitochondrial matrix through three consecutive reactions. ① E1 (pyruvate decarboxylase, TPP-dependent): decarboxylates pyruvate and transfers the acetyl group to E2. ② E2 (dihydrolipoamide acetyltransferase): transfers the acetyl group to CoA, producing acetyl-CoA. ③ E3 (dihydrolipoamide dehydrogenase, FAD- and NAD+-dependent): reoxidizes the reduced dihydrolipoamide, producing NADH.

When the function of this complex is lost, pyruvate cannot be converted to acetyl-CoA and is handled in two directions. First, it is reduced to lactate by lactate dehydrogenase (LDH) (elevated blood lactate). Second, it is aminated to alanine by alanine aminotransferase (ALT) (elevated plasma alanine). Excessive accumulation of these two metabolites forms the biochemical hallmark of lactic acidosis and hyperalaninemia.

As a result of PDH deficiency, the acetyl-CoA supplied to the TCA cycle decreases, and consequently TCA cycle products and ATP production through oxidative phosphorylation decline. The brain mainly uses glucose (→pyruvate→acetyl-CoA→TCA) as its energy source, and because neurons have high mitochondrial density and energy requirements, the brain is particularly vulnerable to PDH deficiency compared with other tissues. The basal ganglia and brainstem are highly dependent on oxidative phosphorylation and are the first to be affected by energy deficiency, which explains the characteristic MRI lesions of Leigh syndrome (symmetric T2 hyperintensity in the basal ganglia and brainstem). Because myelination, neuronal migration and synapse formation in the developing brain are all energy-dependent, PDH deficiency from the fetal through the neonatal period can cause brain malformations (agenesis of the corpus callosum, heterotopic gray matter).

Ketone bodies (β-hydroxybutyrate, acetoacetate) bypass the PDH complex and are converted directly to acetyl-CoA in mitochondria to enter the TCA cycle, so a ketogenic diet can supply alternative energy to the brain. This is the biochemical rationale for ketogenic diet treatment.


6. Symptoms

The clinical spectrum of PDCD is highly diverse depending on residual PDH activity, the causative gene, the X-inactivation pattern (in PDHA1 heterozygous females) and so on. It can be broadly divided into a severe neonatal form, a Leigh syndrome form and an intermittent (mild) form.

Severe neonatal form: In patients with almost no PDH activity, severe lactic acidosis, hyperpyruvatemia, hypotonia and encephalopathy appear immediately after birth. Refusal to feed, lethargy and hyperpnea (respiratory compensation) are observed, and seizures may occur. Blood lactate is extremely elevated (> 15 mmol/L), and metabolic acidosis is severe. Many die or sustain severe neurologic damage in this period. Brain malformations may already have developed before birth, and agenesis of the corpus callosum and cortical dysplasia may be observed on neonatal MRI.

Leigh syndrome form: Characterized by sudden neurologic regression triggered by stress such as infection or fever after normal development in infancy to childhood. Hypotonia, ataxia, eye movement disorders (nystagmus, diplopia, external ophthalmoplegia), dysphagia and respiratory failure occur. Brain MRI characteristically shows bilateral symmetric T2 hyperintense lesions in the basal ganglia (particularly putamen, caudate nucleus), brainstem (particularly around the cerebral aqueduct, pons) and thalamus. Episodic exacerbations and partial recovery repeat, with gradual deterioration.

Intermittent form (mild form): Relatively normal under everyday conditions, but episodes of lactic acidosis are triggered by metabolic stress such as carbohydrate loading (high-carbohydrate meals, intravenous glucose), fever, infection and surgery. Between episodes, there may be mild developmental delay or learning difficulties. Diagnosis may be delayed into adulthood.

Common symptoms include muscle weakness and exercise intolerance, and peripheral neuropathy accompanies the disease in some. In PDHA1 heterozygous females, various clinical presentations are possible, such as mild developmental delay, seizures and periodic episodes of lactic acidosis.


7. Signs

Laboratory findings: ① Elevated blood lactate (lactic acid): > 2.2 mmol/L at rest, > 10–15 mmol/L in the acute phase. ② Elevated blood pyruvate (pyruvic acid): normal < 0.1 mmol/L → elevated. ③ Lactate/pyruvate (L/P) ratio: normal (< 25) or mildly elevated is characteristic in PDCD. In contrast, in respiratory chain deficiency the L/P ratio is markedly elevated (> 25). The L/P ratio is an important indicator for differentiating the two diseases. ④ Marked elevation of plasma alanine (hyperalaninemia). ⑤ Elevated CSF lactate and pyruvate → suggests the presence of lesions in the brain. ⑥ Concurrent blood glucose, ammonia and blood gas analysis.

Brain imaging findings: On MRI, the Leigh syndrome pattern is characterized by bilateral symmetric T2/FLAIR hyperintense lesions in the basal ganglia (putamen, caudate nucleus, globus pallidus), brainstem (midbrain, pons, medulla), thalamus and cerebellum. Agenesis of the corpus callosum (PDHA1 severe neonatal form), cortical dysplasia and ventricular enlargement may be present. MR spectroscopy (MRS) shows an elevated lactate peak (doublet at 1.33 ppm).

Enzyme and molecular findings: PDH complex activity measured in skin fibroblasts, lymphoblasts or muscle tissue — < 30% of normal (severe) or 30–50% (mild). Abnormal mitochondrial morphology may be observed on electron microscopy of muscle biopsy.


8. Screening

A specific universal newborn screening test for PDCD is not currently standardized. Elevated blood alanine (Ala) on newborn MS/MS screening can be a clue, but alanine elevation also occurs from other causes, so specificity is low.

Screening based on clinical suspicion is more realistic. In neonates with unexplained neonatal lactic acidosis (blood lactate > 5 mmol/L), hypotonia, seizures or decreased consciousness, the blood lactate/pyruvate ratio, plasma amino acids (alanine) and urine organic acids (lactate, pyruvate, alpha-ketoglutarate, succinate, etc.) are measured immediately. When the L/P ratio is normal (< 25) with elevated alanine and lactic acidosis, PDCD is suspected first.

When there is a family history, prenatal diagnosis (molecular genetic testing by CVS or amniocentesis) is possible in families in which the causative gene variant has been identified. In X-linked PDHA1 inheritance, the mother's carrier status is checked first.


9. Diagnosis

Confirmation of PDCD combines biochemical testing, enzyme activity measurement and molecular genetic testing.

Plasma and CSF metabolic profile: Simultaneous measurement of blood/CSF lactate and pyruvate and calculation of the L/P ratio. Quantification of plasma alanine. Urine organic acid GC-MS (TCA intermediates such as lactate, pyruvate, malate and α-ketoglutarate).

Brain MRI: confirmation of the Leigh pattern. Evaluation for brain malformations in the neonatal form. MR spectroscopy (lactate peak).

Measurement of PDH complex enzyme activity: Total PDH complex activity is measured in skin fibroblasts (cultured 1–2 weeks) or muscle tissue (radioisotope- or spectrophotometry-based assay). To check thiamine responsiveness, activity is compared before and after adding TPP to the medium.

Molecular genetic testing: NGS of a mitochondrial disease panel including the PDHA1, PDHB, DLAT, DLD and PDHX genes, or whole exome analysis. Complementary MLPA analysis to detect large PDHA1 deletions. Mitochondrial genome sequencing (included for differentiating Leigh syndrome). When a confirmed variant is found, family testing is performed.


10. Treatment

Treatment of PDCD aims at alternative energy supply that bypasses the pyruvate oxidation pathway, amplification of residual PDH activity and correction of lactic acidosis.

Ketogenic diet (KD): The most important treatment for PDCD. A high-fat, low-carbohydrate diet maintaining a fat : (protein + carbohydrate) ratio of 3:1–4:1 provides ketone bodies (β-hydroxybutyrate, acetoacetate) as the brain's main energy source. Because ketone bodies bypass the PDH complex and enter the TCA cycle directly, they can correct brain energy depletion in PDCD patients. An early start (neonatal period) is advantageous for protecting neurodevelopment. Close collaboration with a dietitian is essential, and growth and nutritional status are assessed periodically.

Thiamine (Vitamin B1): In variants near the TPP (thiamine pyrophosphate)-binding site of E1α, high-dose thiamine amplifies residual enzyme activity. A trial of high-dose thiamine (100–2,000 mg/day) is started immediately upon confirmation, and blood lactate and clinical response are assessed. Even without responsiveness, it is generally continued because it is harmless.

Dichloroacetate (DCA): PDH kinase (PDK) inhibition → PDH dephosphorylation → activation of the residual PDH complex. Decreased blood lactate and clinical improvement have been reported in some patients, but caution is needed because peripheral neuropathy has been reported as an adverse effect with long-term use.

Coenzyme Q10 (CoQ10)·L-carnitine·riboflavin: adjunctive therapy to support mitochondrial function. Effect alone is limited, but included in combination regimens. L-carnitine supports fatty acid oxidation and complements ketone production.

Emergency management of acute lactic acidosis: correction of acidosis with intravenous sodium bicarbonate. Intravenous carbohydrate supply is contraindicated (glucose IV increases pyruvate load and may worsen lactic acidosis). Ketone body supply (20% beta-hydroxybutyrate IV) is attempted at some centers.


11. Prognosis

The overall prognosis of PDCD varies greatly depending on the causative gene, variant type, residual PDH activity, age of onset, and treatment response. Overall, prognosis is poor in the severe neonatal form and the Leigh syndrome form.

Prognosis of the severe neonatal form: despite the ketogenic diet and supportive care, severe neurological damage or early death frequently occurs. When accompanied by brain malformations, the neurodevelopmental prognosis is very poor.

Prognosis of the Leigh syndrome form: episodic exacerbations alternate with partial recovery, followed by progressive regression over several years. Avoiding stress episodes such as infection, fever, and surgery is important for preventing exacerbations. The ketogenic diet has been reported to reduce episode frequency and stabilize symptoms in some patients. Life span ranges from several years to several decades, with large individual variation.

Prognosis of the mild intermittent form: a relatively stable course can be maintained with adherence to the ketogenic diet and avoidance of triggering factors. Mild intellectual disability and exercise intolerance persist, but some patients are able to adapt socially. In the mild form first diagnosed in adulthood, episodes can be largely prevented by dietary control alone.


12. Prevention

Primary prevention: because PDHA1 is X-linked, prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT) is available when the mother is a heterozygous carrier. For autosomal recessive (PDHB, DLAT, DLD, PDHX) disease as well, genetic counseling and prenatal diagnosis are recommended for carrier couples. In PDHA1, about 50–65% are de novo variants, so some cases occur without a family history.

Secondary prevention — avoidance of triggering factors: metabolic stresses such as carbohydrate overload (high-carbohydrate meals, intravenous glucose), fever, infection, and surgery trigger lactic acidosis episodes and are therefore actively avoided. During fever and infection, early intensification of the ketogenic diet and inpatient treatment are needed. When surgery is required, a fat-based energy supply plan without glucose administration is established before anesthesia in consultation with anesthesiology and metabolic medicine.

Tertiary prevention — slowing progression: early initiation and strict adherence to the ketogenic diet is most important for slowing the progression of neurological damage. Regular neurodevelopmental assessment, follow-up brain MRI, and early rehabilitation intervention help maintain neurological function. Education of patients and caregivers on the emergency protocol (how to respond during lactic acidosis episodes, criteria for emergency department visits) is essential.


13. References

  1. Patel KP, O'Brien TW, Subramony SH, et al. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012;106(3):385-394. DOI: 10.1016/j.ymgme.2012.03.017. PMID: 22591980.

  2. Brown GK, Otero LJ, LeGris M, et al. Pyruvate dehydrogenase deficiency. J Med Genet. 1994;31(11):875-879. DOI: 10.1136/jmg.31.11.875. PMID: 7853374.

  3. Strafella C, De Feo E, Albanese M, et al. Pyruvate dehydrogenase complex deficiency: a review of treatments and case series. Int J Mol Sci. 2026;27(6):2732. DOI: 10.3390/ijms27062732.

  4. Barnerias C, Saudubray JM, Touati G, et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol. 2010;52(2):e1-9. DOI: 10.1111/j.1469-8749.2009.03541.x. PMID: 19811516.

  5. Wexler ID, Hemalatha SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Neurology. 1997;49(6):1655-1661. DOI: 10.1212/WNL.49.6.1655. PMID: 9409361.

  6. Prasad C, Rupar T, Prasad AN. Pyruvate dehydrogenase deficiency and epilepsy. Brain Dev. 2011;33(10):856-865. DOI: 10.1016/j.braindev.2011.08.004. PMID: 21917399.

  7. Fujii T, Ito M, Takagi T, et al. Pyruvate dehydrogenase deficiency disease detected by the enzyme activity of peripheral leukocytes. Brain Dev. 2021;43(3):337-342. DOI: 10.1016/j.braindev.2020.10.008. PMID: 33349527.

  8. Stacpoole PW. Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase pathway in obesity and metabolic disease. Diabetes Metab Res Rev. 2012;28(3):229-251. DOI: 10.1002/dmrr.1259. PMID: 22287206.

  9. Bourgeron T, Chretien D, Poggi-Bach J, et al. Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J Clin Invest. 1994;93(6):2514-2518. DOI: 10.1172/JCI117261. PMID: 8200988.

  10. Blass JP, Avigan J, Uhlendorf BW. A defect in pyruvate decarboxylase in a child with an intermittent movement disorder. J Clin Invest. 1970;49(3):423-432. DOI: 10.1172/JCI106249. PMID: 5415329.